Great Novel Therapeutics Biotech & Medicals
Taipei Exchange 7427.TWO
Great Novel Therapeutics Biotech & Medicals Price to Sales Ratio (P/S) on January 14, 2025: 260.52
Great Novel Therapeutics Biotech & Medicals Price to Sales Ratio (P/S) is 260.52 on January 14, 2025, a -20.55% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
Great Novel Therapeutics Biotech & Medicals 52-week high Price to Sales Ratio (P/S) is 368.16 on October 23, 2024, which is 41.32% above the current Price to Sales Ratio (P/S).
-
Great Novel Therapeutics Biotech & Medicals 52-week low Price to Sales Ratio (P/S) is 186.09 on August 06, 2024, which is -28.57% below the current Price to Sales Ratio (P/S).
-
Great Novel Therapeutics Biotech & Medicals average Price to Sales Ratio (P/S) for the last 52 weeks is 283.55.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
Taipei Exchange: 7427.TWO
| CEO | Dr. Chia-Nan Chen |
| IPO Date | July 8, 2021 |
| Location | |
| Headquarters | No.508, Zhongxiao East Road |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email